Skip to main content
Article
Abstract CT073: Immunomodulatory effects of nivolumab and ipilimumab in combination or nivolumab monotherapy in advanced melanoma patients: CheckMate 038
Cancer Research (2017)
  • Antoni Ribas, UCLA Medical Center
  • Salvador Martín-Algarra, University of Navarra
  • Shailender Bhatia, University of Washington
  • Wen-Jen Hwu, University of Texas MD Anderson Cancer Center
  • Craig L. Slingluff, University of Virginia
  • William H. Sharfman, Johns Hopkins University
  • F. Stephen Hodi, Harvard University
  • Walter J. Urba
  • Jason J. Luke, University of Chicago
  • John B. Haanen, Cancer Institute
  • Margaret K. Callahan, Memorial Sloan Kettering Cancer Center
  • Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center
  • Scott D. Chasalow, Bristol-Myers Squibb
  • Petra Ross-Macdonald, Bristol-Myers Squibb
  • Tina C. Young, Bristol-Myers Squibb
  • Anila Qureshi, Bristol-Myers Squibb
  • Christine E. Horak, Bristol-Myers Squibb
Publication Date
July 1, 2017
DOI
10.1158/1538-7445.AM2017-CT073
Citation Information
Antoni Ribas, Salvador Martín-Algarra, Shailender Bhatia, Wen-Jen Hwu, et al.. "Abstract CT073: Immunomodulatory effects of nivolumab and ipilimumab in combination or nivolumab monotherapy in advanced melanoma patients: CheckMate 038" Cancer Research Vol. 77 (2017)
Available at: http://works.bepress.com/walter-urba/101/